Read by QxMD icon Read

Prostat cancer

Zhi-Guang Huang, Rong-Quan He, Zeng-Nan Mo
Prostate adenocarcinoma (PRAD) is one of the most common types of malignancy in males and at present, effective prognostic indicators are limited. The development of PRAD has been associated with abnormalities in alternative splicing (AS), a requisite biological process of gene expression in eukaryotic cells; however, the prognostic value of AS products and splicing events remains to be elucidated. In the present study, the data of splicing events and the clinical information of PRAD patients were obtained from The Cancer Genome Atlas (TCGA)SpliceSeq and TCGA databases, respectively...
September 17, 2018: International Journal of Oncology
Jie Liu, Degang Ding, Zhaoqiang Jiang, Tao Du, Jianjun Liu, Zhaohui Kong
BACKGROUND: Macrophage polarization plays an important role in tumor microenvironment, which regulated the prognosis of prostate cancer. However, the potential role of it is still need further identification. METHODS: The M1 Macrophages were inducted using 100 ng/mL LPS and 100 ng/mL IFN-γ, the M1 Macrophages were inducted using 20 ng/mL IL-4. TAMs were obtained by culturing monocytes for 7 days in RPMI 1640 10% FBS with 50% of conditioned medium from PC-3 cells real-time PCR was performed to determine the expression of miR-148a, CCAT1, and PKCζ...
September 16, 2018: Prostate
Laura E Johnson, Dirk Brockstedt, Meredith Leong, Peter Lauer, Erin Theisen, John-Demian Sauer, Douglas G McNeel
Background . Sipuleucel T, an autologous cell-based vaccine targeting prostatic acid phosphatase (PAP), has demonstrated efficacy for the treatment of advanced prostate cancer. DNA vaccines encoding PAP and live attenuated Listeria vaccines have entered clinical trials for patients with prostate cancer, and have advantages in terms of eliciting predominantly Th1-biased immunity. In this study, we investigated whether the immunogenicity and anti-tumor efficacy of a DNA and Listeria vaccine, each encoding PAP, could be enhanced by using them in a heterologous prime/boost approach...
2018: Oncoimmunology
Wanyi Tai, Junwei Li, Eva Corey, Xiaohu Gao
Hurdles in cell-specific delivery of small interfering RNA (siRNA) in vivo hinder the clinical translation of RNA interference (RNAi). A fundamental problem concerns conflicting requirements for the design of the delivery vehicles: cationic materials facilitate cargo condensation and endosomolysis, yet hinder in vivo targeting and colloidal stability. Here, we describe a self-assembled, compact (~30 nm) and biocompatible ribonucleoprotein-octamer nanoparticle that achieves endosomal destabilization and targeted delivery...
2018: Nature Biomedical Engineering
Saurav Mallik, Zhongming Zhao
Background: Marker detection is an important task in complex disease studies. Here we provide an association rule mining (ARM) based approach for identifying integrated markers through mutual information (MI) based statistically significant feature extraction, and apply it to acute myeloid leukemia (AML) and prostate carcinoma (PC) gene expression and methylation profiles. Methods: We first collect the genes having both expression and methylation values in AML as well as PC...
December 2017: Quantitative Biology
Guillaume Vogin, Jean-Louis Merlin, Alexandra Rousseau, Didier Peiffert, Alexandre Harlé, Marie Husson, Labib El Hajj, Mihai Levitchi, Tabassome Simon, Jean-Marc Simon
Purpose: 454 patients with prostate adenocarcinoma were accidentally overexposed to radiation in Epinal hospital, France, between August 1999 and January 2007. We aimed toevaluate whether radiation-induced CD4 or CD8 T-lymphocyte apoptosis (RILA) correlates with the severity of radiation toxicity. Methods: Between 2007 and 2013, all patients who received more than 108% of the prescribed radiation dose, after correction of the treatment plan, were convened, and blood was sampled at 6-months follow-up...
August 24, 2018: Oncotarget
Sanna S Virtanen, Tamiko Ishizu, Jouko A Sandholm, Eliisa Löyttyniemi, H Kalervo Väänänen, Johanna M Tuomela, Pirkko L Härkönen
Bisphosphonates are used for prevention of osteoporosis and metastatic bone diseases. Anti-invasive effects on various cancer cells have also been reported, but the mechanisms involved are not well-understood. We investigated the effects of the nitrogen-containing bisphosphonate alendronate (ALN) on the regulation of actin cytoskeleton in PC-3 cells. We analyzed the ALN effect on the organization and the dynamics of actin, and on the cytoskeleton-related regulatory proteins cofilin, p21-associated kinase 2 (PAK2), paxillin and focal adhesion kinase...
August 24, 2018: Oncotarget
Nityam Rathi, Neysi Anderson, Samantha Greenberg, Jennie Vagher, Neeraj Agarwal, Andrew W Hahn
Germline pathogenic variants (PVs) in DNA-repair genes have garnered increasing attention in metastatic prostate cancer, and more patients are having somatic and germline DNA testing performed. Interpretation of germline DNA testing is a novel challenge for many clinicians, and the results of germline DNA-repair gene testing have significant implications for men with advanced prostate cancer and their children and siblings. Here, we report the case of a man with metastatic castration-refractory prostate cancer and a pathogenic, germline BRCA2 variant...
August 2018: World Journal of Oncology
A Descazeaud, G Robert, A de La Taille
OBJECTIVE: To describe the useful explorations in the clinical evaluation of the symptoms of the lower urinary tract symptoms possibly related to BPH (LUTS/BPH), and to list the information necessary to allow an evaluation of an instrumental or surgical intervention in the treatment of the hypertrophy and benign prostatic obstruction. METHOD: Bibliographic research in English using the European, American and French recommendations on the evaluation of BPH, supplemented by a Pubmed search...
September 13, 2018: Progrès en Urologie
Marcos Luján, Álvaro Páez
No abstract text is available yet for this article.
September 13, 2018: Medicina Clínica
C Huang, G Song, H Wang, G J Ji, Y K Chen, Q He, L Q Zhou
Objective: To develop a nomogram based on prostate imaging reporting and data system version 2 (PI-RADS v2) to predict clinically significant prostate cancer in patients with a prior negative prostate biopsy. Methods: The clinical and pathological data of 231 patients who underwent repeat prostate biopsy and multiparametric MRI (mpMRI) were reviewed. Based on PI-RADS v2, the mpMRI results were assigned as PI-RADS grade from 0 to 2. A Logistic regression nomogram for predicting the probabilities of clinically significant prostate cancer were constructed...
August 28, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Y Luo, M C Li, J H Zhao, Y L Han, Y H Lin, Y X Wang, Y G Jiang, Q Lu, L Lan
Objective: To investigate the role of hypoxia-inducible factor-1α (HIF-1α) and β-catenin in radioresistance of prostate cancer (PCa) cells. Method: Two PCa cell lines, LNCaP and C4-2B, were grouped as: negative control (no treatment), HIF-1α overexpression group (transfected with HIF-1α plasmids), and β-catenin silencing group (transfected with HIF-1α plasmids and β-catenin-shRNA). Cell proliferation, cycle, invasion, and radiosensitivity were measured under normal or hypoxic condition. Radiosensitivity was tested in two mice PCa models (the LNCaP orthotopic BALB/c-nu mice model and the C4-2B subcutaneous SCID mice model)...
August 28, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
X Y Fu, B Y Yang, F L Yin
No abstract text is available yet for this article.
August 28, 2018: Zhonghua Yi Xue za Zhi [Chinese medical journal]
Dounya Schoormans, Pauline A J Vissers, Myrthe P P van Herk-Sukel, Johan Denollet, Susanne S Pedersen, Susanne O Dalton, Nina Rottmann, Lonneke van de Poll-Franse
We examined the incidence of cardiovascular disease (CVD) among 32 757 cancer survivors and age-, gender-, and geographically matched cancer-free controls during a follow-up period of 1-13 years, and explored whetherCVD incidence differed by received cancer treatment, traditional cardiovascular risk factors, age, or gender. Adult 1-year cancer survivors without a history ofCVD diagnosed with breast (n = 6762), prostate (n = 4504), non-Hodgkin (n = 1553), Hodgkin (n = 173), lung and trachea (n = 2661), basal cell carcinoma (BCC; n = 12 476), and colorectal (n = 4628) cancer during 1999-2011 were selected from the Netherlands Cancer Registry and matched to cancer-free controls without a history ofCVD...
September 15, 2018: Cancer Medicine
A Fucic, A Aghajanyan, Z Culig, N Le Novere
Large investments by pharmaceutical companies in the development of new antineoplastic drugs have not been resulting in adequate advances of new therapies. Despite the introduction of new methods, technologies, translational medicine and bioinformatics, the usage of collected knowledge is unsatisfactory. In this paper, using examples of pancreatic ductal adenocarcinoma (PaC) and castrate-resistant prostate cancer (CRPC), we proposed a concept showing that, in order to improve applicability of current knowledge in oncology, the re-clustering of clinical and scientific data is crucial...
September 16, 2018: Pathology Oncology Research: POR
Xavier Palard-Novello, Luc Beuzit, Giulio Gambarota, Florence Le Jeune, Etienne Garin, Pierre-Yves Salaün, Anne Devillers, Solène Querellou, Patrick Bourguet, Hervé Saint-Jalmes
AIM: 18 F-Choline (FCH) uptake parameters are strong indicators of aggressive disease in prostate cancer. Functional parameters derived by magnetic resonance imaging (MRI) are also correlated to aggressive disease. The aim of this work was to evaluate the relationship between metabolic parameters derived by FCH PET/CT and functional parameters derived by MRI. MATERIALS AND METHODS: Fourteen patients with proven prostate cancer who underwent FCH PET/CT and multiparametric MRI were enrolled...
September 15, 2018: Annals of Nuclear Medicine
Barbara Alicja Jereczek-Fossa, Alessia Surgo, Patrick Maisonneuve, Andrea Maucieri, Marianna Alessandra Gerardi, Dario Zerini, Giulia Marvaso, Delia Ciardo, Stefania Volpe, Damaris Patricia Rojas, Giulia Riva, Ombretta Alessandro, Samantha Dicuonzo, Giuseppe Fanetti, Paola Romanelli, Anna Starzyńska, Federica Cattani, Raffaella Cambria, Cristiana Fodor, Cristina Garibaldi, Chiara Romanò, Ottavio De Cobelli, Roberto Orecchia
PURPOSE: To evaluate the incidence and predictors for late toxicity and tumor outcome after hypofractionated radiotherapy using three different image-guided radiotherapy (IGRT) systems (hypo-IGRT) compared with conventional fractionation without image guidance (non-IGRT). METHODS AND MATERIALS: We compared the late rectal and urinary toxicity and outcome in 179 prostate cancer patients treated with hypo-IGRT (70.2 Gy/26 fractions) and 174 non-IGRT patients (80 Gy/40 fractions)...
September 15, 2018: La Radiologia Medica
Karin Sanders, Wesley L de Wit, Jan A Mol, Max Kurlbaum, Sabine Kendl, Matthias Kroiss, Hans S Kooistra, Sara Galac
Abiraterone acetate (AA) is a potent inhibitor of steroidogenic enzyme 17α-hydroxylase/17,20-lyase (CYP17A1). AA is approved for the treatment of prostate cancer, but could also be an interesting treatment of Cushing's syndrome (CS). Similar to humans, canine glucocorticoid synthesis requires CYP17A1, providing a useful animal model. The objective of this study was to preclinically investigate the effect of AA on adrenocortical hormone production, cell viability, and mRNA expression of steroidogenic enzymes in canine primary adrenocortical cell cultures (n = 9) from the adrenal glands of nine healthy dogs...
September 13, 2018: Endocrinology
Sean T Chen, Anne S Hellkamp, Richard C Becker, Scott D Berkowitz, Günter Breithardt, Keith A A Fox, Werner Hacke, Jonathan L Halperin, Graeme J Hankey, Kenneth W Mahaffey, Christopher C Nessel, Jonathan P Piccini, Daniel E Singer, Manesh R Patel, Chiara Melloni
Aims: The management of anticoagulation therapy in patients with atrial fibrillation (AF) and cancer is challenging due to increased thrombotic and bleeding risks. We sought to determine the safety and efficacy of rivaroxaban in patients with AF and a history of cancer. Methods and Results: ROCKET AF randomized 14,264 patients with AF to rivaroxaban or warfarin with a median follow-up of 1.9 years. Cox regression models were used to assess the association between cancer history and clinical outcomes, and the relative treatment effect of rivaroxaban versus warfarin in these patients...
September 14, 2018: European Heart Journal. Quality of Care & Clinical Outcomes
Laura Bukavina, Jon C Tilburt, Badrinath Konety, Nilay D Shah, Cary P Gross, James B Yu, Frederick Schumacher, Alexander Kutikov, Marc C Smaldone, Simon P Kim
BACKGROUND: Magnetic resonance imaging (MRI) of the prostate and fusion biopsy have been advanced to improve the detection of clinically significant prostate cancer (PCa). Yet, frequency of their use and contemporary attitudes among radiation oncologists (ROs) and urologists (UROs) remain largely unknown. OBJECTIVE: We performed a national survey of UROs and ROs to assess the perceived attitudes towards and frequency of prostate MRI and fusion biopsy. DESIGN, SETTING, AND PARTICIPANTS: We conducted a national survey of 915 ROs and 940 UROs about prostate MRI and fusion biopsy in 2017...
September 12, 2018: European Urology Focus
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"